Lv41
435 积分 2021-03-22 加入
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial
6小时前
已完结
Liver fibrosis showed a two-phase regression rate during long-term anti-HBV therapy by three-time biopsies assessments
1个月前
已完结
High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B
1个月前
已完结
Narrow Therapeutic Index Drugs: FDA Experience, Views, and Operations
2个月前
已完结
Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for First‐Time HBV‐Related Decompensated Cirrhosis
2个月前
已完结
Opportunities and challenges for the application of artificial intelligence paradigms into the management of endemic viral infections: The example of Chronic Hepatitis C Virus
2个月前
已完结
Artificial intelligence in liver cancer — new tools for research and patient management
2个月前
已完结
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
2个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
2个月前
已完结
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
3个月前
已完结
皖公网安备34019202002308
